Photometric Activity Assay

Tissue Transglutaminase Pico-Assay Kit


Assay also suitable for FXIII and TG3

Order
Quantity
Price
Status
1 Kit 395 € available


Documents
Art. No. M003
Background info The Tissue Transglutaminase Pico-Assay Kit is based on a high activity high molecular weight substrate (HA-HMS) coated on a solid phase as glutamine-donor and a biotinylated substrate of transglutaminase (Biotinyl-cadaverine) as primary amine. Samples suspected of containing TG2 are incubated with calcium, dithiothreitol (DTT) and biotinyl-cadavarine in the wells of microtiter plates.

Tissue Transglutaminase TG2 Assay for Quantification
Specificity The kit is selective, but not specific for tissue transglutaminase i.e. it also measures FXIII and TG3 activity in samples. Please contact us if calibration for TG3 or FXIII are required. TG1 cannot be measured with this kit.
Assay principle The wells of the solid phase are coated with a specially developed high activity high molecular weight transglutaminase substrate (HA-HMS).
1st reaction: Tissue transglutaminase present in the sample covalently links biotinyl-cadaverine to the high molecular weight substrate (HA-HMS) coated on the microtiter plate surface.
2nd reaction: Streptavidin conjugated to horse-radish peroxidase (HRP) binds to the biotinyl-group incorporated into the HA-HMS solid phase.
3rd reaction: HRP converts a substrate (TMB) into a blue product which upon addition of the stop solution turns yellow. Samples containing transglutaminase activity develop the blue colour (which upon addition of the stop solution turns yellow), whereas samples without activity remain colourless.
Reagents in the kit Microtiter plate
Sample Buffer
Wash Buffer
TG2-Standard for preparation of calibrators
DTT
Reaction Starter Mix
Reaction Stop
Streptavidin-HRP conjugate
Substrate solution
Stop solution
Directions for use
Application Assay for the determination of Tissue Transglutaminase (TG2) activity in the picogram scale
Intended use The present kit is intended for the quantitative determination of tissue transglutaminase activity in a broad application diversity. The kit can also be used for screening of transglutaminase inhibitors.
Storage Store the remaining kit at 4 - 8°C. It is stable up to the expiry date stated on the label of the box. Do not use kit beyond its expiry date. After opening the pouch keep unused microtiter wells resealed to minimize exposure to moisture.
Note Intended for research use only, not for use in human, therapeutic or diagnostic applications.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • 19th International Celiac Disease Symposium

    14.10.2021 - 17.10.2021
    Sorrento, Italy

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA